TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Saturday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.78 on Friday. TherapeuticsMD has a 52 week low of $1.43 and a 52 week high of $4.35. The company’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $2.15.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.31 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to its most recent filing with the SEC. The fund acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.